



SEQUENCE LISTING

<110> Raschke, Eva
Wolffe, Alan P
Case, Casey C

<120> METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN

<130> SABI-006/01US (S12-US1)

<140> 09/844,662

<141> 2001-04-27

<150> 60/200,590

<151> 2000-04-28

<160> 39

<170> PatentIn version 3.2

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: target site 1

<400> 1

ggggaggatc gcggaggctt

20

<210> 2

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence upstream of target site 1

<400> 2

ggggaggatc

10

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: target site 2

<400> 3

gagtgtgtga actgcggggc aa

22

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF 1 F4

<400> 4

Thr Thr Ser Asn Leu Arg Arg

1 5

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF 1 F5

<400> 5

Arg Ser Ser Asn Leu Gln Arg

1 5

<210> 6

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF 1 F6

<400> 6

Arg Ser Asp His Leu Ser Arg

1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF 3a/1 F1

<400> 7

Gln Ser Ser Asp Leu Gln Arg

1 5

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF 3a/1 F2

<400> 8

Arg Ser Ser Asn Leu Gln Arg
1 5

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F3

<400> 9
Arg Ser Asp Glu Leu Ser Arg
1 5

<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F4

<400> 10
Thr Thr Ser Asn Leu Arg Arg
1 5

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F5

<400> 11
Arg Ser Ser Asn Leu Gln Arg
1 5

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F6

<400> 12
Arg Ser Asp His Leu Ser Arg
1 5

<210> 13

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F1

<400> 13
Arg Ser Ala Asp Leu Thr Arg
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F2

<400> 14
Arg Ser Asp His Leu Thr Arg
1 5

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F3

<400> 15
Glu Arg Asp His Leu Arg Thr
1 5

<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: GAT A 15.5 F4

<400> 16
Arg Lys Asp Ser Leu Val Arg
1 5

<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GAT A 15.5 F5

 <400> 17
 Thr Lys Asp His Leu Ala Ser
 1 5

 <210> 18
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: GAT A 15.5 F6

 <400> 18
 Arg Ser Asp Asn Leu Thr Arg
 1 5

 <210> 19
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: VEGF forward
 primer

 <400> 19
 ctggtagcgg ggaggatcg 19

 <210> 20
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: VEGF reverse
 primer

 <400> 20
 gccacgacct ccgagctac 19

 <210> 21
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: VEGF probe

 <400> 21
 ctaccgggct gccccaagcc tc 22

 <210> 22

<211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: pGL-VFR
 forward primer

 <400> 22
 caagtgcagg tgccagaaca 20

 <210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: pGL-VFR
 reverse primer

 <400> 23
 cgggactatg gttgctgact 20

 <210> 24
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: GAPDH forward
 primer

 <400> 24
 ccttttgcag accacagtcc a 21

 <210> 25
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: GAPDH reverse
 primer

 <400> 25
 gcagggatga tggtctggag a 21

 <210> 26
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: GAPDH probe

 <400> 26

cactgccacc cagaagactg tgg 23

<210> 27
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: target
sequence 3

<400> 27
ggggaggag 9

<210> 28
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sequence complementary
to target sequence 3

<400> 28
ctcctcccc 9

<210> 29
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 29
Arg Ser Asp Asn Leu Thr Arg
1 5

<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 30
Arg Ser Asp Asn Leu Thr Arg
1 5

<210> 31
<211> 7
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: zinc finger
recognition helix

<400> 31

Arg Ser Asp Ala Leu Thr Lys
1 5

<210> 32

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ER forward
primer

<400> 32

actggctgct tccögaatc

19

<210> 33

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ER reverse
primer

<400> 33

cgagtggctc agtgtgtgaa cta

23

<210> 34

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ER probe

<400> 34

cgcacaaaca catccacaca ctctctctg

29

<210> 35

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Control
forward primer

<400> 35

ttccgataac gaacgagact ct 22

<210> 36
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Control reverse primer

<400> 36
 tggctgaacg ccacttgtc 19

<210> 37
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Control probe

<400> 37
 taactagtta cgcgaccccc gag 23

<210> 38
 <211> 10
 <212> DNA
 <213> Artificial

<220>
 <223> binding site for a ZFP

<220>
 <221> misc_feature
 <222> (1)..(2)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (3)..(4)
 <223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> N = any nucleotide

<220>
 <221> misc_feature
 <222> (6)..(7)
 <223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<220>

<221> misc_feature
<222> (8)..(8)
<223> N = any nucleotide

<220>
<221> misc_feature
<222> (9)..(10)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<400> 38
nnnnnnnnnn

10

<210> 39
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: NLS

<400> 39
Pro Lys Lys Lys Arg Lys Val
1 5